ESTABLISHMENT LABS HLD. overview

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2023. First Quarter Highlights and Outlook Second quarter worldwide revenue of $48.6 million increased 18.0% year-over-year and was a new quarterly record. 2023 revenue guidance remains $200 million to $210 million, an increase of 24%...

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2023, after the market closes on Tuesday, August 8, 2023, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or (201) 689-8037...

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced the grand opening of the Sulàyöm Innovation Campus in the Coyol Free Zone, Costa Rica. The Sulàyöm Campus will support Establishment Labs’ continued global growth with additional capacity and capabilities in manufacturing, R&D, digital media, training, and medical education. The first...

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investor conferences. Juan José Chacón-Quirós, Chief Executive Officer and Founder, and Raj Denhoy, Chief Financial Officer, will participate in the 2023 Jefferies Healthcare Conference held June 7-9, 2023. Mr. Chacón-Quirós and Mr. Denhoy are scheduled...

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced it has received CE marking under the European Medical Device Regulation for the Motiva Injector ® , the Motiva ® Inflatable Balloon, and the Motiva ® Channel Dissector. “The approval in Europe of our minimally invasive tools is an important step in the evolution of plastic surgery,”...

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2023. First Quarter Highlights and Outlook First quarter worldwide revenue of $46.5 million increased 21.0% year-over-year and was a new quarterly record; excluding the impact of foreign currency changes, revenue growth in the first...

Establishment Labs Holdings Inc. (Nasdaq: ESTA) (the “Company”), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced the closing of its previously announced public offering of 1,265,000 common shares at $71.50 per share. This includes the exercise in full by the underwriters of their option to purchase up to 165,000 additional common shares. The gross proceeds to the Company were...

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2023 after the market closes on Monday, May 8, 2023, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or (201) 689-8037...